Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study

Chen Wang1 Beijing Hospital, Dongcheng District, Beijing, People’s Republic of ChinaCorrespondence[email protected]

Tieying Sun1 Beijing Hospital, Dongcheng District, Beijing, People’s Republic of China

Yijiang Huang2 Hainan Provincial People’s Hospital, Xiuying District, Haikou, People’s Republic of China

Michael Humphries3 Beijing Novartis Pharma Co Ltd, Zhangjiang Hi-Tech Park, Shanghai, People’s Republic of China

Lingyan Bai3 Beijing Novartis Pharma Co Ltd, Zhangjiang Hi-Tech Park, Shanghai, People’s Republic of China

Lilly Li3 Beijing Novartis Pharma Co Ltd, Zhangjiang Hi-Tech Park, Shanghai, People’s Republic of China

Qian Wang3 Beijing Novartis Pharma Co Ltd, Zhangjiang Hi-Tech Park, Shanghai, People’s Republic of China

Pearl Kho4 Novartis Horsham Research Centre, Horsham, West Sussex, UK

Roz Firth4 Novartis Horsham Research Centre, Horsham, West Sussex, UK

Peter D’Andrea5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Your download is now in progress and you may close this window